Is Clinical Practice Aligned with the Latest Scientific Evidence on GAG Therapy?

2017 ◽  
Vol 84 (1_suppl) ◽  
pp. 16-20 ◽  
Author(s):  
Dick A.W. Janssen
Keyword(s):  
Urinary Tract ◽  
Scientific Evidence ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Radiation Cystitis ◽  
Bladder Urothelium ◽  
Bladder Diseases ◽  
Tract Infections

The role of glycosaminoglycans (GAGs) as key components of the protective bladder barrier is well accepted. Replenishment of the GAG layer could restore the normal protective barrier function of the damaged bladder urothelium and re-establish normal permeability. A number of bladder diseases, including interstitial cystitis/ bladder pain syndrome, recurrent urinary tract infections, radiation cystitis, and other forms of cystitis may ben-efit from GAG therapy.

scholarly journals Interstitial cystitis/bladder pain syndrome and recurrent urinary tract infection and the potential role of the urinary microbiome

2020 ◽  
Vol 26 (2) ◽  
pp. 87-90
Author(s):  
Alka Bhide ◽  
Visha Tailor ◽  
Vik Khullar
Keyword(s):  
Urinary Tract ◽  
Interstitial Cystitis ◽  
Urinary Tract Infections ◽  
Potential Role ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Urinary Microbiome ◽  
Tract Infections

Interstitial cystitis/bladder pain syndrome and recurrent urinary tract infections carry significant burden for those affected. As women enter the menopause, other factors may influence how these conditions manifest. The urinary microbiome has shown that the urine contains extensive numbers of bacteria. There is some evidence to suggest that it is altered depending on the menopausal state of the individual. It is possible that this alteration may go on to influence how the disease course of interstitial cystitis/bladder pain syndrome and recurrent urinary tract infections runs in the post-menopausal group. The review will explore these two conditions and the potential role of the urinary microbiome.

Bladder Pain: The Patient Perspective

2017 ◽  
Vol 84 (1_suppl) ◽  
pp. 5-7 ◽  
Author(s):  
Jane M. Meijlink
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Urinary Tract ◽  
Patient Perspective ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Practical Support ◽  
Tract Infections

Patients with chronic pain, discomfort and other urinary symptoms related to bladder pain syndrome or urinary tract infections may experience severely diminished quality of life and psychological and social problems, including depression, anxiety, and a sense of helplessness and hopelessness. These patients require empathy, understanding and practical support to allow them to cope with their chronic bladder disorder.

Urology

2020 ◽  
pp. 83-110
Author(s):  
Helen Jefferis ◽  
Natalia Price
Keyword(s):  
Urinary Tract ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Mechanism Of Injury ◽  
Bladder Pain ◽  
Ureteric Stenting ◽  
Investigation Methods ◽  
Vesicovaginal Fistulae ◽  
Injury And Repair ◽  
Tract Infections

This chapter covers various issues to do with urology in women. It begins by listing different investigation methods and what conditions they are best prepared to show. It then goes through various urological problems that may be encountered, such as ureteric stenting, haematuria, urinary tract infections and non-bacterial cystitis, and bladder pain syndrome. Urethral conditions and injuries to the urinary tract are both covered, including mechanism of injury and repair. Catheters, vesicovaginal fistulae, and urinary diversion are also described and given techniques for management.

Improvements in patients’ quality of life following treatment with intravesical hyaluronic acid (Cystistat 40 mg) for bladder pain syndrome and recurrent UTIs

2020 ◽  
Vol 13 (2) ◽  
pp. 144-149
Author(s):  
Thomas D Brophy ◽  
Sue Fowler ◽  
Louise Clarke ◽  
Andy Thompson
Keyword(s):  
Quality Of Life ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Health Questionnaire ◽  
Bladder Pain ◽  
King’S Health Questionnaire ◽  
Tract Infections

Introduction: Intravesical hyaluronic acid (Cystistat) is indicated for a variety of chronic cystitis conditions including bladder pain syndrome, recurrent bacterial urinary tract infections and radiation or chemical cystitis. Previously published studies have predominantly assessed the outcome in terms of bladder symptoms (frequency/urgency/nocturia/pain) or in the case of recurrent bacterial urinary tract infection, by microbiological response. The aim of this study was to assess improvement in patients’ quality of life following treatment with intravesical Cystistat. Materials and methods: Patients’ referred for treatment with intravesical Cystistat for either bladder pain syndrome or recurrent bacterial urinary tract infection completed the King’s health questionnaire. Patients were treated with a 6-week course of Cystistat by one of two specialist urology nurses. If treatment was effective further instillations were given every 2–4 weeks for up to 6 months. King’s health questionnaire scores were repeated after 6 weeks and 6 months and were analysed. Results: Twenty patients (18 women, 2 men) were included: 8 bladder pain syndrome, 12 recurrent bacterial urinary tract infections. There were four treatment failures within 6 weeks, of whom three were being treated for recurrent bacterial urinary tract infections. Of the 16 patients who continued with treatment beyond 6 weeks, 12 have 6-month scores available. The average initial King’s health questionnaire score was 500.8 (534.1 for the recurrent bacterial urinary tract infection group, 450.8 for the bladder pain syndrome group). After six treatments average King’s health questionnaire scores improved to 426.3 (457.7 for recurrent bacterial urinary tract infections, 372.4 for bladder pain syndrome). After 6 months, average scores significantly improved to 278 overall (303.2 ( P<0.05) for the recurrent bacterial urinary tract infections group, 252.8 ( P>0.05) for the bladder pain syndrome group). Conclusion: Intravesical Cystistat should be considered in all patients with bladder pain syndrome and recurrent bacterial urinary tract infections. We have shown a significant, clinically important, improvement in patients’ quality of life in refractory bladder pain syndrome and recurrent bacterial urinary tract infections. In future Cystistat could be considered as an alternative to long-term low-dose antibiotic prophylaxis. Level of evidence: 4

The Therapeutic Approach to Different forms of Cystitis: Impact on Public Health

2017 ◽  
Vol 84 (1_suppl) ◽  
pp. 8-15
Author(s):  
Stéphane Droupy
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Negative Impact ◽  
Symptom Relief ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Recurrent Urinary Tract Infections ◽  
Bladder Disorders ◽  
Tract Infections

Interstitial cystitis/bladder pain syndrome, recurrent urinary tract infections and other forms of cystitis signifi-cantly impact the quality of life of patients with chronic bladder disorders and impose a considerable economic burden on health systems. Effective management is essential to provide symptom relief and to reduce the negative impact of chronic bladder disorders. Identifying the appropriate pharmacological or non-pharmacological approach is essential, and there is a growing evidence base for the use of intravesical hyaluronic acid and chon-droitin sulfate in several bladder conditions, including recurrent urinary tract infections.

Infections and inflammatory conditions

2019 ◽  
pp. 193-251
Author(s):  
John Reynard ◽  
Simon F Brewster ◽  
Suzanne Biers ◽  
Naomi Laura Neal
Keyword(s):  
Urinary Tract ◽  
Pain Syndrome ◽  
Clinical Problem ◽  
Bladder Pain Syndrome ◽  
Chronic Infections ◽  
Antibiotic Resistant ◽  
Bladder Pain ◽  
Inflammatory Conditions ◽  
Parasite Infections ◽  
Tract Infections

This chapter covers all topics relating to genitourinary tract infections, including basic science and relevant microbiology. The commonest clinical problem of urinary tract infection (UTI) or cystitis is covered in depth, including investigation and management of recurrent UTI. The role of antibiotics both for treatment of active UTI and as prophylaxis is reviewed, along with alternative preventative therapies such methenamine and intravesical drugs. Common acute and chronic infections such as pyelonephritis, prostatitis, and epididymitis, and acute urological emergencies including urosepsis, urethral abscess, sepsis, and Fournier’s gangrene are described. Important chronic conditions including bladder pain syndrome/interstitial cystitis, ketamine bladder, phimosis, and inflammatory conditions of the penis are explained. Less common, but important, exam topics such as tuberculosis and parasite infections (schistosomiasis) of the urinary tract are covered, along with their adverse sequelae. The chapter also explores the essential and highly topical subjects of`antibiotic stewardship and the emergence of antibiotic-resistant organisms.

The surgical options for Hunner’s lesions: an update

2020 ◽  
Vol 13 (3) ◽  
pp. 242-246
Author(s):  
Anthony Simon Bates ◽  
Jaskarn S Rai ◽  
Jonathan Charles Goddard
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Lower Urinary Tract ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Pelvic Cancer ◽  
The Usa ◽  
Surgical Options ◽  
Lower Urinary

Hunner’s lesions, previously described as Hunner’s ulcers, are a component of bladder pain syndrome (BPS), a condition affecting the lower urinary tract, with symptoms of suprapubic pain related to bladder filling, and associated complaints of urgency and frequency. A diagnosis of BPS requires active exclusion of pathology such as constipation, endometriosis, urinary tract infection, bladder stones and pelvic cancer. Women are predisposed to the condition more than men, in a 4:1 ratio. Survey data indicates 2% of women in the USA suffer from BPS. BPS is both physically and emotionally debilitating. In this review, we look at the place of the Hunner’s lesion in BPS and focus on how a lesion might be treated using the available evidence.

Sign in / Sign up

Export Citation Format

Share Document